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Background: Despite increasing clinical use, there is limited data regarding regadenoson in stress perfusion
cardiovascular magnetic resonance (CMR). In particular, given its long half-life the optimal stress protocol remains
unclear. Although Myocardial Perfusion Reserve (MPR) may provide additive prognostic information, current
techniques for its measurement are cumbersome and challenging for routine clinical practice.
The aims of this study were: 1) To determine the feasibility of MPR quantification during regadenoson stress CMR
by measurement of Coronary Sinus (CS) flow; and 2) to investigate the role of aminophylline reversal during
regadenoson stress-CMR.
Methods: 117 consecutive patients with possible myocardial ischemia were prospectively enrolled. Perfusion
imaging was performed at 1 minute and 15 minutes after administration of 0.4 mg regadenoson. A subgroup of 41
patients was given aminophylline (100 mg) after stress images were acquired. CS flow was measured using
phase-contrast imaging at baseline (pre CS flow), and immediately after the stress (peak CS flow) and rest (post CS
flow) perfusion images.
Results: CS flow measurements were obtained in 92% of patients with no adverse events. MPR was significantly
underestimated when calculated as peak CS flow/post CS flow as compared to peak CS flow/pre CS flow (2.43 ±
0.20 vs. 3.28 ± 0.32, p = 0.03). This difference was abolished when aminophylline was administered (3.35 ± 0.44 vs.
3.30 ± 0.52, p = 0.95). Impaired MPR (peak CS flow/pre CS flow <2) was associated with advanced age, diabetes,
current smoking and higher Framingham risk score.
Conclusions: Regadenoson stress CMR with MPR measurement from CS flow can be successfully performed in
most patients. This measurement of MPR appears practical to perform in the clinical setting. Residual hyperemia is
still present even 15 minutes after regadenoson administration, at the time of resting-perfusion acquisition, and is
completely reversed by aminophylline. Our findings suggest routine aminophylline administration may be required
when performing stress CMR with regadenoson.
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Perfusion cardiovascular magnetic resonance (CMR) is
increasingly used for diagnosis and risk stratification of
patients with known or suspected coronary artery disease
(CAD). The majority of these procedures are performed
using the non-selective vasodilator agent adenosine. Rega-
denoson is a relatively new selective adenosine A2A recep-
tor agonist, and is now the most widely used stress agent
in the United States [1]. Unlike adenosine, regadenoson is
conveniently given as a single fixed-dose bolus rather than
as a weight adjusted infusion and is associated with fewer
side-effects [2,3]. However, in contrast to Single-Photon
Emission Computed Tomography (SPECT) imaging [1-3],
there is limited data on regadenoson use in CMR [4-8].
In particular, due to regadenoson’s longer and multi-
exponential clearance [9], a major unresolved issue is
the impact of this on the typical stress-rest CMR stress
protocol. In some centers, reversal is facilitated with ami-
nophylline before resting images are acquired. However,
there is significant variation in current practice and the
role of routine aminophylline reversal is unclear.
Myocardial perfusion reserve (MPR) is the ratio of glo-
bal myocardial blood flow at stress vs. rest. Traditionally,
MPR has been measured non-invasively using quantitative
positron emission tomography (PET) or CMR [10-12].
Several recent studies have suggested that measurement
of MPR provides significant additive prognostic infor-
mation during stress perfusion imaging in patients with
known or suspected CAD [13-16]. However, both PET
and current CMR techniques are cumbersome, and in the
case of PET require radiation as well as on-site Rubidium-
82 generators. Therefore, they are challenging for routine
clinical practice and have been limited to specialized re-
search centers. An alternative, simple CMR method for
measurement of MPR by quantifying change in coronary
sinus (CS) flow has been described [17,18]. The CS drains
approximately 96% of total myocardial blood flow and
provides a potentially convenient location for measurement
of global myocardial blood flow [19]. This method has been
validated against both invasive and PET techniques [18,20].
We hypothesized that measurement of CS flow at stressFigure 1 Regadenoson CMR stress protocol. Stress perfusion protocol s
Coronary sinus flow was measured using phase-contrast imaging at three t
gadolinium enhancement.and rest may provide a simple and rapid assessment of
MPR during regadenoson stress perfusion CMR.
The aims of this study were therefore two-fold: 1) To
determine the feasibility of MPR quantification during
regadenoson stress CMR by measurement of CS flow;




One hundred and seventeen consecutive patients with
suspected myocardial ischemia referred for CMR stress
testing were prospectively enrolled in a single academic
medical center between March 2012 and April 2013.
Patients were excluded if they had metallic implants in-
compatible with CMR, glomerular filtration rate < 30 ml/
min, high degree atrio-ventricular block, severe active
wheezing from asthma or severe claustrophobia. Subjects
were asked to abstain from caffeine-containing products
for at least 12 hours prior to the test. Information on base-
line demographic variables and prior laboratory testing
was obtained from patient interviews and the electronic
medical record. Patients gave informed written consent
for the protocol, which was approved by the University of
Illinois Institutional Review Board.
CMR
Images were acquired on a 3 T scanner (Philips Achieva,
Philips Medical Systems, Best, the Netherlands) using a
six-element phased-array receiver coil. Steady-state free-
precession cine images were acquired in multiple short-
axis and three long-axis views (repetition time 3.0 ms;
echo time 1.5 ms; flip angle 40°; slice thickness 6 mm)
(Figure 1).
The patient table was then partially pulled outside the
scanner bore to allow direct observation of the patient
and full access. A 0.4 mg bolus of regadenoson (Lexiscan,
Astellas Pharma Inc) was infused under continuous elec-
trocardiography and blood pressure monitoring. Approxi-
mately 1 minute after regadenoson administration, the
perfusion sequence was applied and Gadolinium contrasthowing timing of administration of regadenoson and aminophylline.
ime-points (pre-stress, peak stress, and post stress). LGE = late
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by a saline flush (30 ml) was infused (4.5 ml/s) via an ante-
cubital vein. On the console, the perfusion images were ob-
served as they were acquired, with breath-holding starting
from the appearance of contrast in the right ventricular
cavity. Imaging was completed 10 to 15 s after the gado-
linium bolus had transited the left ventricular myocardium.
Perfusion images consisted of three to four short-axis slices
obtained every heartbeat with a saturation-recovery, gra
dient-echo sequence (repetition time 2.8 ms; echo time
1.1 ms; flip angle 20°; voxel size 2.5 × 2.5 × 8 mm). A
random subgroup of 41 patients was administered ami-
nophylline 100 mg IV immediately after stress perfusion
imaging. Rest perfusion images were acquired 15 minutes
after stress imaging with an additional contrast bolus
(0.075 mmol/kg gadoteridol) using identical sequence
parameters. Five minutes after rest perfusion, late ga-
dolinium enhancement (LGE) imaging was performed
with a 2D segmented gradient echo phase-sensitive
inversion-recovery sequence in the identical views as
cine-CMR. Inversion delay times were typically 280 to
360 ms (Figure 1).
Coronary sinus imaging
The coronary sinus was identified in the atrio-ventricular
groove, on the basal slices of the short-axis stack (Figure 2).
The plane for flow measurement was prescribed parallel to
the long-axis of the heart on the 4-chamber view and per-
pendicular to the direction of flow in the coronary sinus,
approximately 0.5 cm from the ostium (green line Figure 2).
Velocity-encoded images were acquired with retrospective
ECG gating during 12- to 18-second breath holds (slice
thickness 6 mm; in-plane resolution 1.3 × 1.3 mm;
temporal resolution 35–55 ms; and velocity encoding
60 cm/s). These images were acquired in the baseline
(pre) state as well as immediately after stress (peak)
and rest (post) perfusion images (Figure 1). In a ran-
dom subgroup of 50 patients the acquisition of the
baseline (pre) and stress (peak) CS images was per-
formed again for assessment of repeatability.Figure 2 Coronary sinus flow measurement. The coronary sinus was iden
stack (panel a). the plane for flow measurement was prescribed parallel to the
direction of flow in the coronary sinus, approximately 0.5 cm from the ostium
cross-section on the phase contrast images (panels c and d). flow vs time cur
sinus to calculate through-plane flow (panel e).CMR analysis
Perfusion and LGE images were visually interpreted by
standard methods [21]. For perfusion-CMR, stress and
rest images were read side-by-side. Blinded quantitative
analysis of CS flow was performed using commercial
software (Philips View Forum, Best, the Netherlands).
The contour of the coronary sinus was traced on the
phase-contrast magnitude images throughout the car-
diac cycle (Figure 2). Coronary sinus flow was calculated
by integrating the momentary flow rate values from each
cardiac phase over the entire cardiac cycle and multiplying
by the mean heart rate during the acquisition (Figure 2).
Coronary sinus flow was calculated at baseline (pre),
immediately after the stress (peak) and at rest (post). A
second blinded physician analyzed the second set of
baseline (pre) and stress (peak) images obtained in the
randomly selected group of 50 patients.
Statistical analysis
Normally distributed data were expressed as mean ± SD.
Interobserver repeatability was analyzed using the
Bland-Altman method [22]. Continuous variables were
compared by the Student’s t-test or Wilcoxon rank-sum
(depending on data normality). Comparisons of discrete
variables were made using the chi-square test; Fisher’s
exact test was used when the assumptions of the chi-




Patients were enrolled at the time of presentation for the
clinically ordered stress CMR scan. All patients gave in-
formed consent. Out of this initial enrolled population
of 117 patients, two patients were excluded due to se-
vere claustrophobia. One of these patients also had se-
vere backache. No patients were seen (or excluded) with
active bronchospasm, high-grade AV block, metallic im-
plants incompatible with CMR, or glomerular filtration
rate < 30 ml/min. Seven patients had inadequate imagetified in the atrio-ventricular groove, on the basal slices of the short-axis
long-axis of the heart on the 4-chamber view and perpendicular to the
(green line, panels a and b). the proximal coronary sinus was seen in
ves were generated by drawing a region of interest around the coronary
Table 1 Baseline characteristics
Characteristic Value
(n = 108)
Age ± SD 60 ± 14
Male sex (%) 50 (46)
Caucasian (%) 20 (19)
Diabetes (%) 34 (31)
Hypertension (%) 79 (73)
Hyperlipidemia (%) 58 (54)
BMI ± SD 31 ± 6
Known CAD (%) 39 (36)
Family history of CAD (%) 24 (22)
Current smoker (%) 21 (19)
Former smoker (%) 24 (22)
Asthma/COPD (%) 6 (5)
Ejection fraction ± SD 65 ± 12
10 yr Framingham risk ± SD 23 ± 18
BMI = body/mass index; CAD = coronary artery disease, COPD = Chronic
Obstructive Pulmonary Disease, GFR = glomerular filtration rate;
SD = standard deviation.
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were inability to breath-hold adequately, poor gating, pa-
tient movement, and inability to identify the coronary
sinus. Therefore the full protocol was successfully com-
pleted in 108 patients (92%) (Figure 3).
Patient characteristics
Table 1 summarizes the baseline patient characteristics.
The mean age of the study population was 60 ± 14 yrs.
Forty-six percent of patients were male and 31% had
diabetes mellitus. Thirty-six percent had known coron-
ary artery disease, and 19% were current smokers. The
mean ejection fraction was 65 ± 12%. The mean 10-year
Framingham risk score was 23 ± 18.
Safety and side effects
Forty-nine percent of patients experienced at least one
side effect after administration of regadenoson (Table 2).
The most commonly reported symptom was shortness
of breath (24%), followed by chest pain (18%), headache
(14%), flushing (13%), nausea (12%), and dizziness (8%).
There were no life-threatening adverse events and no in-
stances of atrio-ventricular block or bronchospasm. In
addition there was no incidence of hypotension, contrast
reactions, heart failure events, unstable angina or pa-
tients requiring antianginal treatment.
Coronary sinus flow measurements
Acquisition of CS images added approximately 2–3 minutes
to overall scanning time with an additional 5 minutes re-
quired for off-line quantitative flow analysis. The flow pro-
file obtained was typically biphasic with a first peak in early
systole and a second peak during early diastole (Figure 2).
Comparison of different myocardial perfusion reserve
calculations
MPR was calculated in two different ways: 1) peak CS flow/
pre CS flow, and 2) peak CS flow/post CS flow (Figure 1).
In the entire study population, MPR calculated as peak CSFigure 3 Study enrollment and completion.flow/pre CS flow was significantly greater than when
calculated as peak CS flow/post CS flow (3.28 ± 0.32 vs.
2.43 ± 0.20, p = 0.03) (Figure 4).
Interobserver repeatability
Bland-Altman analysis of interobserver repeatability for
MPR (calculated as peak CS flow/pre CS flow) showed a
bias of −0.015 (CI −0.056 to 0.026). Limits of agreement
were −0.303 to 0.273. The Bland-Altman plot showed no
systematic bias (Figure 5).
Effects of aminophylline
Table 3 shows baseline patient characteristics of the pa-
tients receiving aminophylline vs those who did not. In
the subgroup of patients receiving aminophylline, there
was no significant difference between MPR calculated as
peak CS flow/post CS flow vs. peak CS flow/pre CS flow
(3.35 ± 0.44 vs. 3.30 ± 0.52, p = 0.95) (Figure 6). In con-









Figure 4 Comparison of different MPR calculations. MPR is significantly greater when using peak CS flow/pre CS flow compared with peak CS
flow/post CS flow.
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greater than MPR calculated as peak CS flow/post CS
flow (3.34 ± 0.44 vs. 1.80 ± 0.52, p = 0.001) (Figure 6).
Figure 7a shows that absolute post CS flow (in ml/min/g)
returned to pre CS values when patients are administered
aminophylline, suggesting complete reversal of residual
hyperemia from regadenoson. In contrast, post CS flow re-
mains elevated compared to pre CS flow in the absence of
aminophylline presumably due to residual hyperemia from
regadenoson (Figure 7b).
Patient characteristics stratified by MPR
Table 4 shows baseline patient characteristics stratified
by MPR < 2 vs MPR ≥ 2. MPR was calculated as peak CSFigure 5 Bland-Altman analysis of interobserver repeatability for MPR
of agreement.flow/pre CS flow. Patients with MPR < 2 were signifi-
cantly more likely to have advanced age, diabetes, higher
Framingham risk score, and history of current smoking.
Discussion
To our knowledge, this is the first study to show that
MPR can be rapidly measured using CS flows in the vast
majority of patients during regadenoson stress CMR.
Acquisition of CS images added approximately 2–3 mi-
nutes to overall scanning time with an additional 5 minutes
required for off-line quantitative flow analysis and is there-
fore practical to perform in the clinical setting. Using this
method, we have demonstrated that MPR is significantly
underestimated when calculated as peak CS flow/post CS. Solid line represents the bias. Dashed lines represent the limits
Table 3 Baseline characteristics of patients receiving aminophylline vs those not receiving Aminophylline
Characteristic Aminophylline No Aminophylline P
Value(n = 41) (n = 67)
Age ± SD 63 ± 17 59 ± 17 0.24
Male sex (%) 22 (54) 28 (42) 0.31
Caucasian (%) 9 (22) 11 (16) 0.54
Diabetes (%) 8 (20) 26 (39) 0.06
Hypertension (%) 31 (76) 48 (72) 0.90
Hyperlipidemia (%) 26 (63) 32 (48) 0.17
Current smoker (%) 8 (20) 13 (19) 0.93
10 yr Framingham risk ± SD 24 ± 14 23 ± 20 0.75
Baseline heart rate 71 ± 12 69 ± 15 0.47
Baseline blood pressure:
Systolic 129 ± 19 124 ± 14 0.12
Diastolic 66 ± 15 68 ± 19 0.57
Peak heart rate 96 ± 17 93 ± 18 0.39
Peak blood pressure:
Systolic 126 ± 18 125 ± 15 0.76
Diastolic 63 ± 15 67 ± 18 0.24
BMI = body/mass index; CAD = coronary artery disease; SD = standard deviation. MPR was calculated as peak CS flow/pre CS flow.
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difference is abolished when aminophylline is adminis-
tered immediately after peak CS flow measurement is
completed. We have shown that this is because in the
absence of aminophylline, residual hyperemia is still
present even 15 minutes after regadenoson adminis-
tration, at the time of resting perfusion acquisition
(Figures 6 and 7).Figure 6 Effect of aminophylline on MPR calculations. In the subgroup
lower when using peak CS flow/post CS flow compared with peak CS flow/pre
between the two methods of calculation. CS = coronary sinus.Comparison with prior studies
A number of prior studies have calculated MPR from
phase-contrast CS flow measurements in man and demon-
strated good agreement with PET [11,23,24]. However,
these were very small studies (n = 9, n = 16 and n = 24) per-
formed in normal volunteers. Koskenvuo et al. measured
MPR with dipyridamole using this approach in 20 patients
with coronary artery disease and also demonstrated goodof patients not receiving aminophylline, MPR measurement is significantly
CS flow. In those receiving aminophylline, there is no difference in MPR
Figure 7 Absolute coronary sinus flow during regadenoson stress protocol. Absolute coronary sinus flow (±SEM) measured at three
time-points (pre-stress, peak stress, post stress). In patients receiving aminophylline (panel a) and in patients not receiving aminophylline (panel b)
demonstrates significant residual hyperemia in the absence of aminophylline.
Table 4 Baseline characteristics stratified by myocardial
perfusion reserve (MPR)





Age ± SD 64 ± 15 58 ± 14 0.04
Male sex (%) 23 (55) 27 (41) 0.16
Caucasian (%) 9 (21) 11 (17) 0.39
Diabetes (%) 18 (43) 16 (24) 0.04
Hypertension (%) 32 (76) 47 (71) 0.57
Hyperlipidemia (%) 23 (55) 35 (53) 0.86
BMI ± SD 31 ± 6 30 ± 6 0.68
Family history of CAD (%) 12 (29) 12 (18) 0.21
Current smoker (%) 13 (31) 8 (12) 0.01
10 yr framingham risk ± SD 29 ± 19 18 ± 16 0.001
BMI = body/mass index; CAD = coronary artery disease; SD = standard
deviation. MPR was calculated as peak CS flow/pre CS flow.
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and demonstrates the feasibility of this approach during
clinical CMR stress in symptomatic patients presenting
with symptoms of possible myocardial ischemia. Our study
population is typical of the type of patients presenting to a
stress CMR service. This method of measuring MPR is
considerably simpler and less labor intensive than trad-
itional quantitative CMR perfusion techniques such as
time-signal intensity analyses. In contrast to prior studies
we have used the relatively new A2A receptor agonist –
regadenoson – which is now the most widely used vaso-
dilator stress agent in the United States [1].
A major finding of our study is that the hyperemic ef-
fect of regadenoson persists even after 15 minutes post
infusion. Similar results were reported in a recent study
by Bhave et al., in which MPR measurements were made
in a sample of 20 healthy volunteers with semi-quantitative
perfusion analysis using the ratio of maximal myocardial
upslopes in the mid-ventricular slice [4]. However, in their
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sidual hyperemia induced by regadenoson. Potential expla-
nations for this discrepancy includes: 1) the much smaller
sample size used in that study compared to ours (n = 20 vs.
n = 117) which increases the possibility of false-positive
findings. 2) Differences between the methods used for
myocardial blood flow measurement, for example they
measured myocardial up-slopes only in the mid-ventricular
slice and no measurements were made of the basal or ap-
ical regions. In contrast blood flow in CS accounts for the
almost all of myocardial blood flow. 3) Their study in-
cluded only healthy volunteers, which may differ from our
population of patients with known or suspected coronary




The epicardial coronary arteries represent only a tiny
fraction of the overall coronary circulation - which ex-
tends from the large epicardial conduit arteries through
pre-arterioles, arterioles and capillaries before eventually
draining back through the venous system into the coronary
sinus [25]. MPR depends not only on trans-stenotic pres-
sure gradient of the epicardial arteries and thus stenosis
severity but even more on the ability of the coronary mi-
crovasculature (especially the pre-arterioles) to dilate [25].
Therefore, coronary microvascular dysfunction, which im-
pairs pre-arteriolar function, reduces MPR independently
of the presence of epicardial coronary stenosis [25]. Table 4
shows baseline patient characteristics stratified by MPR < 2
vs MPR ≥ 2. Patients with impaired MPR (<2) were signifi-
cantly more likely to have advanced age, diabetes, higher
Framingham risk score, and history of current smoking.
These findings are consistent with the known effects of
these risk factors on the coronary microvascular function
[25]. Thus the ability to quantitatively measure MPR may
allow a more comprehensive understanding of chest pain
syndromes and, in particular, of microvascular dysfunction.
Indeed, several recent studies using PET have suggested
that measurement of MPR provides significant additive
prognostic information during stress perfusion imaging in
patients with known or suspected CAD [13-16]. However
measurement of MPR with both PET and current CMR
techniques are cumbersome, and in the case of PET re-
quire radiation as well as on-site Rubidium-82 generators.
Therefore, they are challenging for routine clinical practice
and have been limited to specialized research centers. In
this study we have shown that MPR can be rapidly and
simply measured using phase-contrast imaging of CS flow
during regadenoson stress CMR. We have demonstrated
that this is feasible in the large majority of typical patients
referred for this procedure. Recent trials have shown the
high diagnostic accuracy of stress CMR for the detectionof epicardial coronary artery disease [26]. The addition of a
simple, rapid method of MPR measurement may provide
an additional tool in the CMR armamentarium for eval-
uating coronary microvascular physiology and pathology
which maybe of importance in a number of conditions
including coronary artery disease, Syndrome X and
hypertrophic cardiomyopathy. Future studies are needed to
determine whether this measurement of MPR during rega-
denoson stress perfusion can provide additive prognostic
information as has been demonstrated by PET [13-16].
Role of aminophylline
The pharmacokinetics of regadenoson are complex, with
an initial phase half-life of approximately 2–4 minutes,
followed by an intermediate and late phase, with the lat-
ter having a half-life of 2 hours [3,9]. Indeed, we have
shown that myocardial blood flow remains elevated des-
pite waiting at least 15 min. Thus in order to avoid
underestimating MPR, we would recommend measuring
MPR as peak CS flow/pre CS flow rather than peak CS
flow/post CS flow. Alternatively either measurement can
be used if aminophylline is administered since it reverses
the residual hyperemic effect of regadenoson.
The implications of this persistent hyperemia extend
beyond the accurate calculation of MPR. If post CS flow
does not truly represent pre CS flow (i.e. basal myocardial
blood flow), the diagnostic accuracy of the test to detect is-
chemia may be affected. A region of hypoperfusion that is
present at both stress and rest is typically interpreted as
artifact [21]. However, if there is persistent hyperemia dur-
ing the “resting” perfusion images then this region may ac-
tually represent ischemia. One potential solution for this
would be to perform rest perfusion images prior to stress
images ensuring that rest perfusion is truly performed
under basal flow conditions. The drawback of this protocol
is the risk that gadolinium contrast may accumulate in
infarcted areas and potentially mask inducible ischemic re-
gions in subsequent stress perfusion images [27]. An add-
itional advantage of a stress followed by rest protocol, is
that if stress perfusion images are completely normal and
free from artifact, the rest perfusion images can sometimes
be omitted resulting in a faster protocol. An alternate so-
lution would be to reverse the vasodilatory effect of regade-
noson immediately after acquisition of stress perfusion
images in every case. Our data show that myocardial blood
flow does, indeed, return to basal conditions after aminoph-
ylline injection. Thus, routine administration of aminophyl-
line after vasodilator stress will allow for “clean” resting
perfusion images that represent basal flow conditions.
Limitations
There are a number of important limitations to our study
that must be borne in mind. The normal adult CS diam-
eter has been reported as being around 8.3 ± 2.5 mm at
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1.3 × 1.3 mm only a limited number of voxels will be lo-
cated within the lumen of the vessel resulting in partial
volume errors. Moreover, the CS is a mobile structure
resulting in errors from through and in-plane motion.
Misalignment of the imaging plane is another potential
source of error. Another major cause of concern is phase-
offset errors - particularly given the low velocities in the
CS [29]. We did not use phantoms or stationary correc-
tion schemes for this study partly to keep scanning and
post-processing times within the limits of a typical clinical
protocol. There is also considerable anatomic variation in
cardiac venous anatomy. In particular, the insertion of the
medial cardiac vein maybe very close to the orifice of the
CS and thus its contribution to flow volume maybe
missed. One might postulate that some of these sources of
error may primarily impact absolute blood flow measure-
ments rather than MPR, since presumably similar errors
occur under both stress and rest conditions. In this study
we did not perform a direct head-to-head comparison of
MPR derived from CS flow compared to a standard such
as PET since good agreement has previously been reported
[11,18,23,24]. Moreover, the association of impaired MPR
(<2) in our study with advanced age, diabetes, current
smoking and higher Framingham risk score is consistent
with the known effects of these variables on coronary
microvascular function (Table 4). In this study we did not
use other doses or timings of aminophylline administra-
tion. However we have shown that 100 mg of aminophyl-
line given in the protocol described reverses the residual
hyperemia which would otherwise be present. Although
patients were asked to withhold caffeine for at least
12 hours as recommended in the regadenoson package
insert, caffeine levels were not drawn to assess for compli-
ance. In this study, patients were referred by their cardiol-
ogists for clinically indicated scans. It is likely that our
referring cardiologists were aware of CMR contraindica-
tions leading to some degree of referral bias since we saw
no patients with active bronchospasm, high-grade AV
block, metallic implants incompatible with CMR, or sig-
nificant renal failure during the study period. ECG
monitoring in the CMR environment remains challen-
ging and is a limitation of stress-CMR. Finally, although
we were able to obtain MPR measurement in the vast
majority of patients (108 out of 117 i.e. 92%), there were
a few cases where patients were unable to complete the
protocol or image quality was too poor for this to be
possible.
Conclusions
We have shown that MPR calculation from CS flow
measurements can be successfully performed in the vast
majority of symptomatic patients with known or sus-
pected coronary artery disease. Measurement of MPRwas relatively rapid and is practical to perform in the
clinical setting. Further studies are needed to determine
whether this measure of MPR during regadenoson
stress perfusion can provide additive prognostic or diag-
nostic information. We found that residual hyperemia is
still present even 15 minutes after regadenoson admin-
istration, at the time of resting perfusion acquisition.
However, this can be completely reversed by aminophyl-
line. Therefore in a stress-rest CMR protocol, MPR should
be calculated as peak CS flow/pre CS flow – particularly
if aminophylline is not given. Moreover, our findings
imply that it may be preferable to routinely give
aminophylline when performing stress-rest CMR per-
fusion using regadenoson, in order to avoid possible
misinterpretation of perfusion defects from lingering
hyperemia on the “resting” perfusion scans.
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